Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Journal
Therapeutic advances in medical oncology
Journal Volume
15
Date Issued
2023
Author(s)
Slamon, Dennis J
Fasching, Peter A
Hurvitz, Sara
Chia, Stephen
Crown, John
Martín, Miguel
Barrios, Carlos H
Bardia, Aditya
Im, Seock-Ah
Yardley, Denise A
Untch, Michael
et al.,
Abstract
Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. New Adjuvant Trial with Ribociclib [LEE011] (NATALEE) is a trial evaluating the efficacy and safety of adjuvant ribociclib plus endocrine therapy (ET) versus ET alone in patients with HR+/HER2- early nonmetastatic breast cancer (EBC).
Subjects
CDK4/6 inhibitors; HR+/HER2– early breast cancer; NATALEE; adjuvant therapy; ribociclib
SDGs
Type
journal article